real-time news and commentary for investors
Monday, Jun 3
An FDA panel is due to vote this week on whether to lift the restrictions on Avandia,...
An FDA panel is due to vote this week on whether to lift the restrictions on Avandia, GlaxoSmithKline's (GSK +0.3%) former blockbuster diabetes pill whose sales plummeted after the agency said in 2010 that it could only be used only in rare cases due to fears that it caused heart attacks. Following a new positive analysis of old data, two panels will decide whether to remove, modify or leave Avandia's safety restrictions in place, or withdraw the drug entirely.